FDA Commissioner Scott Gottlieb announced Thursday (Nov. 2) that FDA is expanding its Expanded Access Navigator, which aims to facilitate pre-approval access to drugs , to include drugs that treat orphan diseases. “Making sure there’s a close relationship with the efforts we take to expand pre-approval access to promising treatments, and the work of our orphan drugs program, is a key step toward maximizing opportunities for patients,” Gottlieb wrote in an FDA Voice blog. The move will help patients gain...